Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

RCEL
Avita Medical, Inc. Common Stock
stock NASDAQ ADR

Market Open
Sep 9, 2025 12:30:32 PM EDT
4.21USD0.000%(0.00)52,109
4.21Bid   4.23Ask   0.02Spread
Pre-market
Sep 9, 2025 8:59:30 AM EDT
4.26USD+1.188%(+0.05)1,376
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
08:00AM EST  RECELLSystem Data to be Presented at 44th   GlobeNewswire Inc
Jan 11, 2022
10:38AM EST  52 Weeks High And Low Article   Benzinga
Jan 10, 2022
08:53AM EST  AVITA Medical Sees Q2 Revenue $6.9M Vs $7M Est   Benzinga
08:00AM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2021.   GlobeNewswire Inc
Jan 6, 2022
04:03PM EST  AVITA Medical Completes Enrollment In Pivotal Trial Evaluating The RECELL System For Soft-Tissue Reconstruction   Benzinga
04:01PM EST  AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the   GlobeNewswire Inc
08:00AM EST  AVITA Medical Establishes Proof of Concept for Novel Treatments   GlobeNewswire Inc
Dec 15, 2021
04:02PM EST  AVITA Medical Completes Enrollment In Pivotal Trial Evaluating The RECELL System For Repigmentation Of Stable Vitiligo   Benzinga
04:01PM EST  AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the   GlobeNewswire Inc
Dec 14, 2021
07:02PM EST  AVITA Medical, Inc. Announces Adjournment of 2021 Annual   GlobeNewswire Inc
Nov 16, 2021
04:01PM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:   GlobeNewswire Inc
Nov 9, 2021
11:17AM EST  Recap: AVITA Medical Q1 Earnings   Benzinga
11:02AM EST  AVITA Medical Sees Q2 Sales ~$7M Vs. $7.19M Est.   Benzinga
11:02AM EST  Avita Therapeutics Q1 EPS $(0.24) Beats $(0.38) Estimate, Sales $7.00M Miss $7.10M Estimate   Benzinga
Nov 8, 2021
04:01PM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first fiscal quarter ended September 30, 2021.   GlobeNewswire Inc
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Nov 3, 2021
09:19AM EDT  AVITA Medical Announces Expanded Medicare Reimbursement To Outpatient Hospital And Ambulatory Surgical Centers   Benzinga
08:00AM EDT  AVITA Medical Announces Expanded Medicare Reimbursement to   GlobeNewswire Inc
Oct 25, 2021
04:01PM EDT  AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results   GlobeNewswire Inc
Sep 13, 2021
04:01PM EDT  AVITA Medical to Present at the 2021 Cantor Virtual Global   GlobeNewswire Inc
Aug 31, 2021
04:01PM EDT  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021.   GlobeNewswire Inc
Aug 26, 2021
04:04PM EDT  AVITA Medical Sees Q1 Sales $7M vs $6.39M Est.   Benzinga
04:03PM EDT  Avita Therapeutics Q4 EPS $(0.19) Beats $(0.29) Estimate, Sales $10.30M Beat $7.88M Estimate   Benzinga
04:01PM EDT  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.   GlobeNewswire Inc
04:02AM EDT  Earnings Scheduled For August 26, 2021   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
10:36AM EDT  FDA Approves AVITA Medical Vitiligo Trial With Fewer Participants   Benzinga
08:22AM EDT  FDA Approves IDE Amendment To A Single-Arm Design For AVITA Medical's Pivotal Study Of The RECELL System For Vitiligo Treatment   Benzinga
08:00AM EDT  -- New single-arm design to evaluate 23 subjects at 15 clinical sites, versus previously approved 3-arm study of 84 subjects -- The 1:20 expansion ratio to be used is the best-case scenario for patients as it requires the least amount of donor skin   GlobeNewswire Inc
Aug 12, 2021
04:01PM EDT  AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results   GlobeNewswire Inc
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 29, 2021
04:24PM EDT  AVITA Medical Announces Co. Was Included In The Russell 3000 Index As Of June 28th, 2021   Benzinga
04:23PM EDT  AVITA Medical Announces Inclusion in the Russell 3000 Index   GlobeNewswire Inc
Jun 16, 2021
08:20AM EDT  The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO   Benzinga
07:28AM EDT  AVITA Medical Late Yesterday Raised Its Q4 Sales Guidance From $8.2M-$8.6M To $9.5M-$9.7M   Benzinga
Jun 15, 2021
06:08PM EDT  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.   GlobeNewswire Inc
Jun 10, 2021
09:01AM EDT  AVITA Medical Says FDA Approves Expanded Use Of RECELL System For Treatment Of Extensive Burns And Pediatric Patients   Benzinga
09:00AM EDT  U.S. Food and Drug Administration Approves Expanded Use of the   GlobeNewswire Inc
Jun 1, 2021
04:01PM EDT  AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (AVITA Medical), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021.   GlobeNewswire Inc
May 13, 2021
04:23PM EDT  AVITA Medical Sees Q4 Sales $8.2M-$8.6M Vs $8.21M Estimates   Benzinga
04:20PM EDT  Avita Therapeutics Q3 Sales $8.77M Beat $6.37M Estimate   Benzinga
04:01PM EDT  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its third quarter of fiscal year 2021, ended March 31, 2021.   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
Apr 15, 2021
08:00AM EDT  New RECELL System Data to be Presented at 43rd Annual   GlobeNewswire Inc
Mar 30, 2021
04:02PM EDT  AVITA Medical Says 15 Abstracts Highlighting Benefits Of RECELL Accepted For Presentation At American Burn Association Meeting   Benzinga
04:01PM EDT  15 RECELL System Abstracts Accepted for Presentation   GlobeNewswire Inc
Mar 22, 2021
08:16AM EDT  AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer   Benzinga
Mar 2, 2021
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021   Benzinga
06:36AM EST  Piper Sandler Initiates Coverage On AVITA Medical with Overweight Rating, Announces Price Target of $27   Benzinga
Mar 1, 2021
06:33PM EST  Avita Medical, Inc. Announces Closing of Offering of 3,214,250   GlobeNewswire Inc
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
06:46AM EST  AVITA Medical Prices 2.795M Share Common Stock Offering At $21.50/Share   Benzinga
Feb 24, 2021
04:11PM EST  AVITA Medical Reports Offering Of Common Stock, No Size Disclosed   Benzinga
04:01PM EST  AVITA Medical, Inc. Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Feb 18, 2021
04:01PM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:   GlobeNewswire Inc
Feb 11, 2021
04:02PM EST  Avita Therapeutics Q2 EPS $(0.26) Beats $(0.43) Estimate, Sales $5.10M Miss $5.60M Estimate   Benzinga
04:01PM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its second quarter of fiscal year 2021, ended December 31, 2020.   GlobeNewswire Inc
03:51AM EST  Earnings Scheduled For February 11, 2021   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 3, 2021
04:01PM EST  AVITA Medical to Present at the BTIG Virtual MedTech, Digital   GlobeNewswire Inc
Jan 12, 2021
08:15AM EST  AVITA Medical Sees Q4 2020 Revs $5M Vs Est $5.82M   Benzinga
08:14AM EST  AVITA Medical Expects Q2 Total Global Revenue To Be $5.1 Mln   RTTNews
08:00AM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2020.   GlobeNewswire Inc
Jan 11, 2021
05:16PM EST  AVITA Medical Sees Total Global Revs. $5.1M In Q2 2021   Benzinga
Dec 28, 2020
05:00PM EST  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. Eastern Time.   GlobeNewswire Inc
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 17, 2020
09:29AM EST  Tessa Therapeutics Appoints David McIntyre As CFO   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
08:00AM EST  Abstracts Highlighting Clinical and Health Economic Data ReinforceEffectiveness of Treatment with RECELL System   GlobeNewswire Inc
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 1, 2020
08:06AM EST  AVITA Therapeutics Names Kathy McGee COO   Benzinga
08:00AM EST  AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.   GlobeNewswire Inc
Nov 18, 2020
04:01PM EST  AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020.   GlobeNewswire Inc
Nov 11, 2020
09:40AM EST  Avita Therapeutics shares were trading higher after the company reported Q1 EPS and sales results up from last year.   Benzinga
Nov 10, 2020
04:07PM EST  Avita Therapeutics Q1 EPS $0.48 Up From $0.19 YoY, Sales $5.10M Up From $3.30M YoY   Benzinga
04:01PM EST  AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fiscal first quarter of 2021, ended September 30, 2020.   GlobeNewswire Inc
08:00AM EST  AVITA Therapeutics, Inc.: Results of 2020 Annual Meeting of   GlobeNewswire Inc
Nov 9, 2020
08:30AM EST  AVITA Therapeutics And The Houston Methodist Research Institute Enter Into Collaboration To Explore Novel Approaches For Skin Rejuvenation, No Terms Disclosed   Benzinga
08:00AM EST  Preclinical research will pair AVITA TherapeuticsSpray-On Skin Cells with Houston Methodist Research Institutestechnologies to reverse cellular aging   GlobeNewswire Inc
Nov 5, 2020
07:46AM EST  Avita Therapeutics, Inc. Announces Correction of Time for the   GlobeNewswire Inc
Nov 3, 2020
04:02PM EST  AVITA Therapeutics Announces Date Change For First Quarter 2021 Earnings Release and Conference Call From Nov. 11 To Nov. 10   Benzinga
04:01PM EST  AVITA Therapeutics Announces Date Change for First Quarter 2021   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Oct 28, 2020
04:01PM EDT  AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will participate in the following upcoming investor conferences.   GlobeNewswire Inc
Oct 27, 2020
04:01PM EDT  AVITA Therapeutics to Announce First Quarter 2021 Financial Results   GlobeNewswire Inc
Sep 14, 2020
08:06AM EDT  AVITA Therapeutics Announces First Patient Enrolled In Pivotal Study Evaluating RECELL System For Repigmentation Of Stable Vitiligo   Benzinga
08:00AM EDT  First Patient Enrolled in AVITA Therapeutic's Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo   Business Wire
Sep 3, 2020
04:01PM EDT  AVITA Therapeutics to Participate in Upcoming Investor Conferences   Business Wire
Aug 27, 2020
10:44AM EDT  B of A Securities Initiates Coverage On Avita Therapeutics with Buy Rating, Announces Price Target of $42   Benzinga
Aug 26, 2020
08:13AM EDT  AVITA Therapeutics Says Expects To Treat First Vitiligo Patient In Sept 2020; Expects Quarterly Sales To Exceed Previously Reported $3.9M;   Benzinga
08:08AM EDT  AVITA Therapeutics Provides Company Update   RTTNews
08:00AM EDT  AVITA Therapeutics Provides Company Update and Revised Corporate Presentation   Business Wire
Jul 29, 2020
04:01PM EDT  AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference   Business Wire
Jul 13, 2020
08:09AM EDT  BARDA To Initiate Procurement Of The RECELL System For Emergency Response Preparedness   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC